<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-title>Lipids in Health and Disease</journal-title><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16948861</article-id><article-id pub-id-type="pmc">1570348</article-id><article-id pub-id-type="publisher-id">1476-511X-5-24</article-id><article-id pub-id-type="doi">10.1186/1476-511X-5-24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The use of a <italic>Cissus quadrangularis </italic>formulation in the management of weight loss and metabolic syndrome</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Oben</surname><given-names>Julius</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>juliusoben@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Kuate</surname><given-names>Dieudonne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dkuatefr@yahoo.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Agbor</surname><given-names>Gabriel</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>agogae@yahoo.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Momo</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>momo_claudia@yahoo.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Talla</surname><given-names>Xavio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>xavio_talla@uy1-lnnb.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biochemistry, University of Yaound&#x000e9; I, Yaound&#x000e9;, Cameroon</aff><aff id="I2"><label>2</label>Institute of Medical Research &#x00026; Medicinal Plant studies, Yaounde, Cameroon</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>2</day><month>9</month><year>2006</year></pub-date><volume>5</volume><fpage>24</fpage><lpage>24</lpage><ext-link ext-link-type="uri" xlink:href="http://www.lipidworld.com/content/5/1/24"/><history><date date-type="received"><day>14</day><month>7</month><year>2006</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Oben et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Oben et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Oben
               Julius
               
               juliusoben@hotmail.com
            </dc:author><dc:title>
            The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome
         </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Lipids in Health and Disease 5(1): 24-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-511X(2006)5:1&#x0003c;24&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-511X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Aim</title><p>Once considered a problem of developed countries, obesity and obesity-related complications (such as metabolic syndrome) are rapidly spreading around the globe. The purpose of the present study was to investigate the use of a <italic>Cissus quadrangularis </italic>formulation in the management of metabolic syndrome, particularly weight loss and central obesity.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study was a randomized, double-blind, placebo-controlled design involving 123 overweight and obese persons (47.2% male; 52.8% female; ages 19&#x02013;50). The 92 obese (BMI &#x0003e;30) participants were randomized into three groups; placebo, formulation/no diet, and formulation/diet (2100&#x02013;2200 calories/day). The 31 overweight participants (BMI = 25&#x02013;29) formed a fourth (no diet) treatment group. All participants received two daily doses of the formulation or placebo and remained on a normal or calorie-controlled diet for 8 weeks.</p></sec><sec><title>Results</title><p>At the end of the trial period, statistically significant net reductions in weight and central obesity, as well as in fasting blood glucose, total cholesterol, LDL-cholesterol, triglycerides, and C-reactive protein were observed in participants who received the formulation, regardless of diet.</p></sec><sec><title>Conclusion</title><p><italic>Cissus quadrangularis </italic>formulation appears to be useful in the management of weight loss and metabolic syndrome.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Although still defined in diverse terms, metabolic syndrome is a common disorder arising as a result of the increased prevalence of obesity throughout the world [<xref ref-type="bibr" rid="B1">1</xref>]. Metabolic syndrome, also known as insulin resistance syndrome and Syndrome X, has 3 main potential etiologic categories: obesity and disorders of adipose tissue; insulin resistance; and a constellation of independent factors (e.g., molecules of hepatic, vascular, and immunologic origin) that mediate specific components of the metabolic syndrome [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>In the United States, over 60% of the adult population is now overweight or obese [<xref ref-type="bibr" rid="B3">3</xref>] and 47 million people have metabolic syndrome, which will soon overtake cigarette smoking as the number one risk factor for heart disease [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Globally, the disorder has become a major public health challenge. (In Cameroon, approximately 25% of the population is now considered obese.)</p><p>Obesity has been shown to contribute to high serum cholesterol, low HDL cholesterol and hyperglycemia, all of which increase the chances of cardiovascular disease (CVD) [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. Correlations between central obesity and high blood pressure, high blood cholesterol, low levels of high density lipoprotein-cholesterol, and high fasting blood glucose levels have been shown for both sexes in various racial and ethnic groups [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Since it has been determined that abdominal fat poses a greater health risk than fat stored in the lower half of the body [<xref ref-type="bibr" rid="B11">11</xref>], waist circumference has become a major factor in body-fat assessment [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. A large waist circumference (&#x0003e;88 cm in women and 102 cm in men) is associated with an increased risk for type 2 diabetes, dyslipidemia, hypertension and CVD in patients with a body mass index (BMI) 25&#x02013;34 [<xref ref-type="bibr" rid="B8">8</xref>]. Moreover, for obese patients with metabolic complications, changes in waist circumference are useful predictors of CVD risk factors [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Thus, in addition to weight (kg), fat (%) and BMI, changes in waist measurement (cm) was one of the primary endpoints in this study.</p><p>Because of its links with obesity, it is difficult to identify a unique role for insulin resistance in patients with metabolic syndrome. Although insulin resistance generally rises with increasing body fat content, one finds a broad range of insulin sensitivities at all levels [<xref ref-type="bibr" rid="B6">6</xref>]. Although most people with BMI &#x02265; 30 have postprandial hyperinsulinemia and relatively low insulin sensitivity, there is variation in insulin sensitivity even within the obese population [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Overweight persons (BMI 25&#x02013;29) also exhibit a spectrum of insulin sensitivities, which seems to suggest an inherited component to insulin resistance.</p><p>The increased chance of CVD and type 2 diabetes require therapeutic consideration for the vast numbers of overweight/obese persons now at high risk for these diseases [<xref ref-type="bibr" rid="B1">1</xref>]. The current International Diabetes Foundation recommendations for preventing or delaying the development of diabetes include both primary and secondary interventions. The former emphasizes lifestyle changes such as calorie restriction and increased physical activity, and the latter (for people at high risk for CVD) uses pharmacological agents [<xref ref-type="bibr" rid="B15">15</xref>] that specifically target individual components of metabolic syndrome [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. When used by obese patients in combination with dietary regimes, these agents can produce some weight loss and some reversal of accompanying complications. The role of pharmacotherapy, however, has been compromised by safety issues leading to the withdrawal of some medications from the market [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. The combination of safety concerns and high costs have forced many populations to continue to rely on traditional healing methods using the indigenous pharmacopoeia.</p><p><italic>Cissus quadrangularis</italic>, for example, is used by common folk in India to hasten the fracture healing process [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B28">28</xref>]. In Cameroon, the whole plant is used in oral re-hydration, while in Africa and Asia the leaf, stem, and root extracts are utilized in the management of various ailments [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B33">33</xref>]. Phytochemical analyses of <italic>Cissus quadrangularis </italic>reveal a high content of ascorbic acid, carotene, phytosterol substances and calcium [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>], and there have also been reports of the presence of &#x003b2;-sitosterol, &#x003b4;-amyrin and &#x003b4;-amyrone [<xref ref-type="bibr" rid="B36">36</xref>]. All these components have potentially different metabolic and physiologic effects [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. Although researchers have investigated several uses of Cissus quadrangularis, its potential application against metabolic syndrome has not yet been reported.</p><p>Several other dietary supplements (green tea, soy, chromium, selenium, B-vitamins) have only marginal effects in treating obesity but they address other metabolic syndrome symptoms and thus were included in the formulation. Green tea (<italic>Camellia sinensis</italic>) extracts contain high concentrations of epigallocatchin gallate and may work with other chemicals to increase levels of fat oxidation and thermogenesis [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. Numerous studies on soy (<italic>Glycine max</italic>) protein show it is associated with a reduction in serum cholesterol and triglyceride levels and suggest it may protect against the development of coronary heart disease [<xref ref-type="bibr" rid="B41">41</xref>]. Chromium helps insulin metabolize fat, turn protein into muscle, and convert sugar into energy [<xref ref-type="bibr" rid="B42">42</xref>]; thus, chromium supplementation can favorably influence glucose/insulin metabolism, reduce levels of harmful LDL cholesterol, and increase HDL cholesterol [<xref ref-type="bibr" rid="B43">43</xref>]. Both humans and animals require selenium for the optimal functioning of the <italic>selenoproteins</italic>, which reduce the risk of CVD by decreasing lipid peroxidation and influencing the metabolism of the cell-signaling prostaglandins [<xref ref-type="bibr" rid="B44">44</xref>]. Lastly, B-vitamins (B-6, B-12 and folic acid) regulate energy metabolism [<xref ref-type="bibr" rid="B45">45</xref>], which plays a critical role in obesity management; they also maintain lower homocysteine levels [<xref ref-type="bibr" rid="B46">46</xref>], which are closely associated with cardiovascular health benefits.</p><p>The purpose of the present study was to examine the efficacy of a <italic>Cissus quadrangularis </italic>formulation (Cylaris&#x02122;) containing the above agents in the management of obesity and metabolic syndrome.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study was a prospective, randomized, double blind, placebo-controlled design conducted by the Laboratory for Nutrition and Nutritional Biochemistry at the University of Yaound&#x000e9; I, Cameroon, Africa. The Cameroon National Ethics Committee approved the protocol. Applicants were advised of the study's purpose, nature, and potential risks, and all gave their written informed consent before participation. The study was conducted in accordance with the Helsinki Declaration (1983 version).</p><sec><title>Participants</title><p>Eligibility criteria included meeting the minimal standards for overweight (i.e., a BMI &#x0003e;25 and a waist circumference &#x0003e;85.5 cm.) and a willingness to participate in an 8-week trial. Exclusion criteria (confirmed via an initial interview and physical examination) included pregnancy/lactatation, use of any form of weight-reducing medication, participation in intense exercise programs, medical conditions known to affect serum lipids, and a history of drug or alcohol abuse. For the 123 eligible participants, BMIs ranged from 25.5 to 45.6; waist circumferences from 85.5 cm to 125 cm; and weight from 62.6 kg to 142 kg. (See Table <xref ref-type="table" rid="T1">1</xref> for other baseline characteristics.) Ninety-two persons qualified as obese (BMI &#x0003e;30), and 31 as overweight (BMI = 25&#x02013;29). The age range was 19 to 50; males = 47.2%; females = 52.8%.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline (week 0) characteristics of study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">BMI</td><td align="center" colspan="3">Greater than 30 (Obese)</td><td align="left">25 &#x02013; 29 (Overweight)</td></tr></thead><tbody><tr><td align="left">Treatment</td><td align="left">Placebo (n = 30)</td><td align="left">Formulation/no diet (n = 31)</td><td align="left">Formulation/Diet (n = 31)</td><td align="left">Formulation/no diet (n = 31)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Demographic Characteristics </bold>(no.)</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Sex</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Male</td><td align="left">14</td><td align="left">15</td><td align="left">14</td><td align="left">15</td></tr><tr><td align="left">&#x02003;Female</td><td align="left">16</td><td align="left">16</td><td align="left">17</td><td align="left">16</td></tr><tr><td align="left">Age (years)*</td><td align="left">39.9 (9.6)</td><td align="left">41.0 (9.4)</td><td align="left">40.9 (9.8)</td><td align="left">39.7 (9.9)</td></tr><tr><td align="left">Race or ethnic group</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;West African</td><td align="left">30</td><td align="left">31</td><td align="left">31</td><td align="left">31</td></tr><tr><td align="left">Family History of Diabetes</td><td align="left">2</td><td align="left">1</td><td align="left">0</td><td align="left">2</td></tr><tr><td align="left">History of Gestational Diabetes</td><td align="left">2</td><td align="left">2</td><td align="left">3</td><td align="left">2</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Anthropomorphic Characteristics*</bold><sup><bold>1</bold></sup></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Weight (kg)</td><td align="left">95.6 (14.3)</td><td align="left">95.8 (8.0)</td><td align="left">95.3 (9.1)</td><td align="left">76.3 (7.9)</td></tr><tr><td align="left">Fat (%)</td><td align="left">41.8 (5.2)</td><td align="left">46.5 (5.8)</td><td align="left">48.1 (3.0)</td><td align="left">35.8 (5.2)</td></tr><tr><td align="left">Body Mass Index (kg/m<sup>2</sup>)</td><td align="left">38.4 (1.6)</td><td align="left">37.7 (1.5)</td><td align="left">37.5 (1.0)</td><td align="left">27.3 (0.7)</td></tr><tr><td align="left">Waist Circumference (cm)</td><td align="left">103.4 (8.1)</td><td align="left">98.6 (4.6)</td><td align="left">97.8 (5.7)</td><td align="left">86.9 (3.2)</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Serological Characteristics*</bold><sup><bold>2</bold></sup></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Total Cholesterol (mg/dl)</td><td align="left">160.8 (18.0)</td><td align="left">159.1 (30.7)</td><td align="left">171.0 (24.4)</td><td align="left">152.6 (26.9)</td></tr><tr><td align="left">LDL Cholesterol (mg/dl)</td><td align="left">103.5 (14.9)</td><td align="left">99.8 (11.7)</td><td align="left">116.6 (15.4)</td><td align="left">101.6 (17.0)</td></tr><tr><td align="left">HDL Cholesterol (mg/dl)</td><td align="left">32.7 (7.5)</td><td align="left">36.6 (8.0)</td><td align="left">38.6 (7.1)</td><td align="left">44.4 (9.8)</td></tr><tr><td align="left">Triglycerides (mg/dl)</td><td align="left">142.5 (31.8)</td><td align="left">156.0 (25.3)</td><td align="left">144.9 (30.0)</td><td align="left">117.4 (25.3)</td></tr><tr><td align="left">C-Reactive Protein (mg/dl)</td><td align="left">8.0 (1.1)</td><td align="left">8.0 (1.0)</td><td align="left">8.1 (0.7)</td><td align="left">7.8 (0.8)</td></tr><tr><td align="left">Fasting Blood Glucose (mg/dl)</td><td align="left">101.6 (11.9)</td><td align="left">101.2 (15.9)</td><td align="left">102.4 (9.8)</td><td align="left">93.3 (12.4)</td></tr></tbody></table><table-wrap-foot><p>* These data are shown as means with standard deviations in parentheses</p><p><sup>1 </sup>Primary outcome measures</p><p><sup>2 </sup>Secondary outcome measures</p></table-wrap-foot></table-wrap></sec><sec><title>Intervention</title><p>The 92 obese persons were randomized to a placebo or one of two treatment groups; the 31 overweight persons formed a fourth group. One obese treatment group was prescribed a calorie-controlled (2100&#x02013;2200 calories/day) diet; none of the groups was prescribed an exercise regimen. Apart from the expected lower anthropomorphic and serological characteristics of the overweight group, none of the baseline differences between the groups was clinically significant.</p><p>The overweight group was used for general comparison with the obese groups, thus the results were expressed in percentages rather than absolute values. The formulation/diet group was used to determine if a short-term, calorie-controlled diet would significantly increase anthropomorphic and serological outcomes compared to the formulation/non-diet group.</p></sec><sec sec-type="materials"><title>Materials</title><p>The <italic>Cissus quadrangularis </italic>formula, Cylaris&#x02122;, contains a <italic>Cissus quadrangularis </italic>extract (supplied by Gateway Health Alliances, Inc, Fairfield, California, USA), standardized to contain a minimum of 2.5% phytosterols and a minimum of 15% soluble plant fiber. The formula also consists of a soy albumin extract (supplied by Gateway Health Alliances, Inc, Fairfield, California, USA); a green tea extract standardized to 22% EGCG and 40% caffeine; niacin bound chromium (ChromeMate&#x02122; supplied by InterHealth Nutraceuticals, Inc, Benicia, California, USA); selenium standardized to 0.5% l-Selenomethionine; vitamin B6 (as pyridoxine hydrochloride); vitamin B12 (as cyanocobalamin); and folic acid (supplied by Protein Research, Inc, Livermore, California, USA). All active and placebo capsules were manufactured and bottled by Protein Research, Inc.</p><p>Participants received two daily doses (514 mg each) of the <italic>Cissus </italic>formulation or placebo for 8 weeks. Each capsule was taken with 8&#x02013;12 oz of water immediately prior to meals (preferably breakfast and dinner). In keeping with the experimental design, the capsules were identical in shape, color and appearance, and neither the participants nor researchers knew which capsule was administered. Side effects were noted on each visit.</p><p>Body weight and percentage of body fat were determined in the 12-hour- fasted participants with a Tanita&#x02122; BC-418 Segmental Body Composition Analyzer/Scale that uses bio-electrical impedance analysis for body composition analysis. Height was measured with a Harpended&#x02122; stadiometer, which measures the length of curved line staffage to the nearest 0.5 cm.</p><p>Blood (5 ml) samples were collected after an overnight fast at the start and end of the 8 week trial period. The blood was collected into vacutainer tubes, and the serum was separated (via centrifugation) and stored (200 &#x003bc;l aliquots) at -20&#x000b0;C until needed for analyses. The concentrations of total cholesterol, triacylglycerol, HDL-cholesterol, LDL-cholesterol, and glucose were measured using commercial diagnostic kits (cholesterol Infinity, triglyceride Infinity, EZ HDL&#x02122; cholesterol, EZ LDL&#x02122; cholesterol, Glucose Trinder) from SIGMA Diagnostics. C-reactive protein was measured using an ELISA method (BioCheck&#x02122; hsC-Reactive Protein ELISA kit, Foster City, CA USA).</p></sec><sec><title>Statistical analyses</title><p>The data for each parameter was summarized via n, mean, and standard deviation for Week 0 and Week 8 and the percent difference (Week 8 &#x02013; Week 0/week 0). The percent change from baseline was tested for differences using analysis of variance. Contrasts were used for testing pair-wise differences.</p></sec></sec><sec><title>Results</title><sec><title>Anthropomorphic characteristics</title><p>Waist circumference is an extremely important determinant in the diagnosis of obesity and metabolic syndrome. As shown in Table <xref ref-type="table" rid="T2">2</xref>, the significant reduction in this variable across all treatment groups was paralleled by significant reductions in weight and BMI for the two obese treatment groups.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Effectiveness of <italic>Cissus quadrangularis </italic>formulation on anthropomorphic characteristics: Percent difference in means from Week 0 to Week 8</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">BMI</td><td align="center" colspan="3">Greater than 30 (Obese)</td><td align="left">25 &#x02013; 29 (Overweight)</td></tr></thead><tbody><tr><td align="left">Treatment</td><td align="left">Placebo (n = 30)</td><td align="left">Formulation/no diet (n = 31)</td><td align="left">Formulation/Diet (n = 31)</td><td align="left">Formulation/no diet (n = 31)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Anthropomorphic Characteristics*</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Weight (%)</td><td align="left">-2.4 (4.9)</td><td align="left">-6.9 (6.8)<sup>c</sup></td><td align="left">-8.5 (11.3)<sup>a</sup></td><td align="left">-4.8 (6.0)</td></tr><tr><td align="left">Fat (%)</td><td align="left">-1.9 (9.6)</td><td align="left">-6.0 (8.4)</td><td align="left">-8.0 (7.6)<sup>b</sup></td><td align="left">-4.7 (9.4)</td></tr><tr><td align="left">Body Mass Index (%)</td><td align="left">-1.0 (4.2)</td><td align="left">-8.3 (3.8)<sup>a</sup></td><td align="left">-9.9 (2.7)<sup>a</sup></td><td align="left">-3.9 (3.0)<sup>a</sup></td></tr><tr><td align="left">Waist Circumference (%)</td><td align="left">-2.0 (7.2)</td><td align="left">-6.6 (4.9)<sup>a</sup></td><td align="left">-8.4 (6.7)<sup>a</sup></td><td align="left">-11.2 (4.7)<sup>a</sup></td></tr></tbody></table><table-wrap-foot><p>* These data are shown as means with standard deviations in parentheses</p><p><sup>a </sup>P = &#x0003c;0.001 versus placebo</p><p><sup>b </sup>P = &#x0003c;0.01 versus placebo</p><p><sup>c </sup>P = &#x0003c;0.05 versus placebo</p></table-wrap-foot></table-wrap><p>To translate the percentage loss over 8 weeks into actual measurements, the mean change in weight (kg) for the 3 obese (BMI &#x0003e;30) groups was 95.6 to 93.3 (placebo); 95.8 to 89.2 (formulation/no diet); and 95.3 to 87.2 (formulation/diet). The mean change for the overweight (BMI 25 &#x02013; 29) group was 76.3 to 72.6 kg (formulation/no diet).</p><p>Thus, over a period of 8 weeks, the placebo group lost 2.3 kg; the overweight group lost 3.7 kg and the two obese groups lost 6.6 kg and 8.1 kg, respectively.</p></sec><sec><title>Serological characteristics</title><p>As shown in Table <xref ref-type="table" rid="T3">3</xref>, there was a significant improvement in virtually every measurement for the three treatment groups vs. placebo. Eight-week use of the <italic>Cissus </italic>formulation significantly reduced plasma total cholesterol and LDL cholesterol in the three treatment groups and increased HDL cholesterol in the two obese groups by 50.5 % and 43.0% The increase in the concentration of circulating HDL-cholesterol in the three treatment groups shows a large reduction in the ratio of total cholesterol to HDL-cholesterol ratios as well as LDL-cholesterol to HDL-cholesterol ratios. All three treatment groups also demonstrated a significant decrease in triglycerides, C- reactive protein, and fasting blood glucose levels.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Effectiveness of <italic>Cissus quadrangularis </italic>formulation on serological characteristics: Percent difference in means from Week 0 to Week 8</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">BMI</td><td align="center" colspan="3">Greater than 30 (Obese)</td><td align="left">25 &#x02013; 29 (Overweight)</td></tr></thead><tbody><tr><td align="left">Treatment</td><td align="left">Placebo (n = 30)</td><td align="left">Formulation/no diet (n = 31)</td><td align="left">Formulation/Diet (n = 31)</td><td align="left">Formulation/no diet (n = 31)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Serological Characteristics*</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Total Cholesterol (%)</td><td align="left">-3.1 (28.7)</td><td align="left">-27.0 (14.6)<sup>a</sup></td><td align="left">-26.0 (13.3)<sup>a</sup></td><td align="left">-18.8 (17.0)<sup>b</sup></td></tr><tr><td align="left">LDL Cholesterol (%)</td><td align="left">-10.4 (13.4)</td><td align="left">-18.4 (9.8)<sup>c</sup></td><td align="left">-32.4 (15.5)<sup>a</sup></td><td align="left">-26.4 (12.8)<sup>a</sup></td></tr><tr><td align="left">HDL Cholesterol (%)</td><td align="left">17.4 (38.8)</td><td align="left">50.5 (50.7)<sup>b</sup></td><td align="left">43.0 (39.5)<sup>c</sup></td><td align="left">19.6 (37.0)</td></tr><tr><td align="left">Triglycerides (%)</td><td align="left">-4.5 (25.4)</td><td align="left">-36.8 (17.8)<sup>a</sup></td><td align="left">-28.0 (12.2)<sup>a</sup></td><td align="left">-15.0 (15.3)<sup>c</sup></td></tr><tr><td align="left">C-Reactive Protein (%)</td><td align="left">0.8 (13.2)</td><td align="left">-20.8 (11.2)<sup>a</sup></td><td align="left">-20.8 (10.0)<sup>a</sup></td><td align="left">-16.3 (13.2)<sup>a</sup></td></tr><tr><td align="left">Fasting Blood Glucose (%)</td><td align="left">-4.6 (14.8)</td><td align="left">-13.4 (13.6)<sup>b</sup></td><td align="left">-16.1 (13.4)<sup>a</sup></td><td align="left">-11.4 (11.8)<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p>* These data are shown as means with standard deviations in parentheses</p><p><sup>a </sup>P = &#x0003c;0.001 versus placebo</p><p><sup>b </sup>P = &#x0003c;0.01 versus placebo</p><p><sup>c </sup>P = &#x0003c;0.05 versus placebo</p></table-wrap-foot></table-wrap><p>To translate the percentage loss over 8 weeks into actual measurements, the mean change in Total cholesterol (mg/dl) for the 3 obese (BMI &#x0003e;30) groups was 160.8 to 155.8 (placebo); 159.1 to 116.1 (formulation/no diet); and 171.0 to 126.5 (formulation/diet. The mean change for the overweight (BMI 25 &#x02013; 29) group was 152.6 to 123.9.</p><p>Thus, over a period of 8 weeks, Total cholesterol declined 5.0 mg/dl for the placebo group; 28.7 mg/dl for the overweight group; and 43.0 mg/dl and 44.5 mg/dl for the two obese groups.</p><sec><title>Adverse events</title><p>Adverse events with an incidence &#x0003e;5 included headache (12), gas (11), dry mouth (7), diarrhea (7), and insomnia (6). Since the incidence of all reported side effects was always higher in the placebo group than in any of the treatment groups, it is probably safe to conclude that the <italic>Cissus formulation </italic>had few, if any, negative side effects.</p></sec></sec></sec><sec><title>Discussion</title><p>Our results support the hypothesis that the use of a <italic>Cissus quadrangularis </italic>formulation has efficacy in the management of weight loss and metabolic syndrome, particularly for central obesity. The use of the formulation (which also contains green tea, soy, chromium, selenium, and B-vitamins) over an 8-week period brought about a significant reduction in many of the anthropomorphic measures: weight, % body fat, BMI and, especially, waist circumference of obese and overweight patients, regardless of calorie-controlled diet (see Table <xref ref-type="table" rid="T2">2</xref>).</p><p>Waist circumference is a particularly important factor in weight and body-fat assessment since fat distribution, rather than total body fat, is currently the key indicator of weight-related health problems. The dramatic reduction in waist circumference that accompanied the 8-week use of the <italic>Cissus quadrangularis </italic>formulation for both the diet and no diet groups is particularly important because waist circumference is a major criterion in the diagnosis of obesity and metabolic syndrome [<xref ref-type="bibr" rid="B2">2</xref>] and is generally considered a surrogate measure for abdominal visceral fat [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Moreover, not only does the risk of type 2 diabetes increase with the degree and duration of obesity it, too, is associated with central obesity [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The reduction in the primary anthropomorphic measurements can be attributed to the synergistic effects of Cylaris&#x02122;, <italic>Glycine max </italic>extract, <italic>Camellia sinensis </italic>extract and ChromeMate&#x02122; ingredients in the formula, all of which have previously been shown to affect weight loss activity [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>].</p><p><italic>Cissus quadrangularis </italic>phytosterols and fiber extracts have been shown to have anti-lipase, and anorexiant properties that reduce the absorption of dietary fats and enhance satiation by increasing serum serotonin levels [<xref ref-type="bibr" rid="B47">47</xref>]. In 1999, Swiss researchers found that men who were given a combination of caffeine and green tea catechin extract burned more calories than those given only caffeine or a placebo. It was postulated that the catechins and caffeine combination sustained the effect of norepinephrine on thermogenesis longer than caffeine alone [<xref ref-type="bibr" rid="B39">39</xref>]. Numerous studies on chromium supplementation have also demonstrated weight loss in overweight and obese people [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. Grant et al. (1997) reported that chromium with a moderate diet and exercise regimen influences weight loss and body composition [<xref ref-type="bibr" rid="B50">50</xref>].</p><p>The modification of certain serological characteristics (blood parameters) (see Table <xref ref-type="table" rid="T3">3</xref>) by <italic>Cissus </italic>formulation may or may not be dependent on weight loss. Only the reduction of LDL-cholesterol followed a similar pattern to weight loss over the 8-week trial period. The circulating concentration of total cholesterol and triglycerides, though reduced by the formulation, could be independent of weight loss since all treatment groups (diet/no diet) showed significant cholesterol reduction. The increase in the concentration of circulating HDL-cholesterol in the treatment groups shows a reduction in the ratio of total cholesterol to HDL-cholesterol as well as LDL-cholesterol to HDL-cholesterol. This reduced ratio also implies a reduction in the risk of atherosclerosis and coronary heart disease [<xref ref-type="bibr" rid="B51">51</xref>].</p><p>Although the exact mechanisms for the formulation's cholesterol-lowering ability needs further study, the various ingredients might interact in a manner similar to statins, fibrates, probucol, nicotinic acid or cholesterol absorption inhibitors. Green tea catechins have a number of antioxidant activities related to cholesterol regulation. For example, the inhibition of the oxidation of low-density lipoproteins and the antithrombotic activity both aid in lowering total cholesterol/LDL-cholesterol and increasing HDL-cholesterol levels [<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B53">53</xref>]. Also, the phytochemical constituents (phytosterols, &#x003b2;-sitosterol, &#x003b4;-amyrin and &#x003b4;-amyrone), in <italic>Cissus quadrangularis </italic>may have activity similar to other plant sterols. The molecular structure of phytosterols, for example, is practically identical to that of cholesterol.</p><p>Recent studies show that metabolic syndrome causes an inflammatory process in the blood vessels that leads to arteriosclerosis. This inflammatory process can be gauged by blood levels of C-reactive protein [<xref ref-type="bibr" rid="B54">54</xref>] and, as our results showed, <italic>Cissus </italic>formulation significantly reduced the circulating concentrations of CRP thereby inhibiting the inflammatory process and possibly reducing individual components of metabolic syndrome [<xref ref-type="bibr" rid="B54">54</xref>]. In metabolic syndrome, the body becomes resistant to insulin, and high levels of glucose remain trapped in the blood. In response, the pancreas produces more insulin. The extra insulin temporarily allows glucose to enter the cells and also increases cholesterol and triglyceride levels.</p><p>In sum, <italic>Cissus </italic>formulation administered twice daily to obese and overweight persons with symptoms of metabolic syndrome results in both weight reduction and an improvement in the symptoms associated with metabolic syndrome. It has also shown efficacy in the control and lowering of triglyceride concentrations, total cholesterol, LDL-cholesterol, and fasting blood glucose. The formulation may also have applications in other metabolic diseases, such as diabetes mellitus.</p></sec><sec><title>Authors' contributions</title><p>JO conceived, designed, coordinated and drafted the manuscript; DK carried out blood sampling and performed statistical analyses; GA participated in the design and carried out analytical work; CM participated in the design and carried out analytical work; XT participated in the formulation of the extract.</p><p>All the authors read and approved the final manuscript.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>The metabolic syndrome</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1415</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">15836891</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66378-7</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Brewer</surname><given-names>HB</given-names><suffix>Jr</suffix></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Smith</surname><given-names>SC</given-names></name><name><surname>Lenfant</surname><given-names>C</given-names></name></person-group><article-title>Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">14744958</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000111245.75752.C6</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokdad</surname><given-names>AH</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Bowman</surname><given-names>BA</given-names></name><name><surname>Dietz</surname><given-names>WH</given-names></name><name><surname>Vinicor</surname><given-names>F</given-names></name><name><surname>Bales</surname><given-names>VS</given-names></name><name><surname>Marks</surname><given-names>JS</given-names></name></person-group><article-title>Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>76</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">12503980</pub-id><pub-id pub-id-type="doi">10.1001/jama.289.1.76</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Dietz</surname><given-names>WH</given-names></name></person-group><article-title>Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Examination Survey</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>356</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">11790215</pub-id><pub-id pub-id-type="doi">10.1001/jama.287.3.356</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YW</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Palaniappan</surname><given-names>L</given-names></name><name><surname>Heshka</surname><given-names>S</given-names></name><name><surname>Carnethon</surname><given-names>M</given-names></name><name><surname>Heymsfield</surname><given-names>S</given-names></name></person-group><article-title>The metabolic syndrome prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988&#x02013;1994</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><fpage>427</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12588201</pub-id><pub-id pub-id-type="doi">10.1001/archinte.163.4.427</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>BW</given-names><suffix>Jr</suffix></name><name><surname>Lamendola</surname><given-names>C</given-names></name><name><surname>McLaughlin</surname><given-names>T</given-names></name><name><surname>Reaven</surname><given-names>GM</given-names></name></person-group><article-title>Relationship between obesity, insulin resistance, and coronary heart disease risk</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><fpage>937</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">12225719</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(02)02051-X</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogardus</surname><given-names>C</given-names></name><name><surname>Lillioja</surname><given-names>S</given-names></name><name><surname>Mott</surname><given-names>DM</given-names></name><name><surname>Hollenbeck</surname><given-names>C</given-names></name><name><surname>Reaven</surname><given-names>G</given-names></name></person-group><article-title>Relationship between degree of obesity and in vivo insulin action in man</article-title><source>Am J Physiol</source><year>1985</year><volume>248</volume><fpage>e286</fpage><lpage>e291</lpage><pub-id pub-id-type="pmid">3883799</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Giles</surname><given-names>TD</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Yuling</surname><given-names>H</given-names></name><name><surname>Stern</surname><given-names>J</given-names></name><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name></person-group><article-title>Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>898</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">16380542</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.171016</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><name><surname>Sullivan</surname><given-names>L</given-names></name><name><surname>Parise</surname><given-names>H</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group><article-title>Overweight and obesity as determinants of cardiovascular risk: the Framingham experience</article-title><source>Arch Intern Med</source><year>2002</year><volume>162</volume><fpage>1867</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">12196085</pub-id><pub-id pub-id-type="doi">10.1001/archinte.162.16.1867</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denke</surname><given-names>MA</given-names></name><name><surname>Sempos</surname><given-names>CT</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name></person-group><article-title>Excess body weight: an under-recognized contributor to high blood cholesterol levels in white American women</article-title><source>Arch Intern Med</source><year>1994</year><volume>154</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">8117172</pub-id><pub-id pub-id-type="doi">10.1001/archinte.154.4.401</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ochs-Balcom</surname><given-names>HM</given-names></name><name><surname>Grant</surname><given-names>BJ</given-names></name><name><surname>Muti</surname><given-names>P</given-names></name><name><surname>Sempos</surname><given-names>CT</given-names></name><name><surname>Freudenheim</surname><given-names>JL</given-names></name><name><surname>Trevisan</surname><given-names>M</given-names></name><name><surname>Cassano</surname><given-names>PA</given-names></name><name><surname>Iacoviello</surname><given-names>L</given-names></name><name><surname>Schunemann</surname><given-names>HJ</given-names></name></person-group><article-title>Pulmonary function and abdominal adiposity in the general population</article-title><source>Chest</source><year>2006</year><volume>129</volume><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">16608930</pub-id><pub-id pub-id-type="doi">10.1378/chest.129.4.853</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paek</surname><given-names>KW</given-names></name><name><surname>Hong</surname><given-names>YM</given-names></name></person-group><article-title>Health behavior factors affecting waist circumference as an indicator of abdominal obesity</article-title><source>J Prev Med Pub Health</source><year>2006</year><volume>39</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">16613073</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuk</surname><given-names>JL</given-names></name><name><surname>Katzmarzyk</surname><given-names>PT</given-names></name><name><surname>Nichaman</surname><given-names>MZ</given-names></name><name><surname>Church</surname><given-names>TS</given-names></name><name><surname>Blair</surname><given-names>SN</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Visceral fat is an independent predictor of all-cause mortality in men</article-title><source>Obesity</source><year>2006</year><volume>14</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">16571861</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pouliot</surname><given-names>MC</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><name><surname>Lemieux</surname><given-names>S</given-names></name><name><surname>Moorjani</surname><given-names>S</given-names></name><name><surname>Bouchard</surname><given-names>C</given-names></name><name><surname>Tremblay</surname><given-names>A</given-names></name><name><surname>Nadeau</surname><given-names>A</given-names></name><name><surname>Lupien</surname><given-names>PJ</given-names></name></person-group><article-title>Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal adipose tissue accumulation and related cardiovascular risk in men and women</article-title><source>Am J Cardiol</source><year>1994</year><volume>73</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">8141087</pub-id><pub-id pub-id-type="doi">10.1016/0002-9149(94)90676-9</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Fowler</surname><given-names>SE</given-names></name><name><surname>Hamman</surname><given-names>RF</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name><name><surname>Walker</surname><given-names>EA</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name></person-group><article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>393</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">11832527</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa012512</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyorala</surname><given-names>K</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Gumbiner</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Mitchel</surname><given-names>YB</given-names></name><name><surname>Pedersen</surname><given-names>TR</given-names></name><name><surname>Kjekshus</surname><given-names>J</given-names></name></person-group><article-title>Reduction of cardiovascular events by Simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1735</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">15220255</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>TA</given-names></name><name><surname>Xianag</surname><given-names>AH</given-names></name><name><surname>Peters</surname><given-names>RK</given-names></name><name><surname>Kjos</surname><given-names>SL</given-names></name><name><surname>Marroquin</surname><given-names>A</given-names></name><name><surname>Goico</surname><given-names>J</given-names></name><name><surname>Ochoa</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Berkowitz</surname><given-names>K</given-names></name><name><surname>Hodis</surname><given-names>HN</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name></person-group><article-title>Preservation of pancreatic &#x003b2;-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>2796</fpage><lpage>2803</lpage><pub-id pub-id-type="pmid">12196473</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chanoine</surname><given-names>JP</given-names></name><name><surname>Hampl</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Boldrin</surname><given-names>M</given-names></name><name><surname>Hauptman</surname><given-names>J</given-names></name></person-group><article-title>Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial</article-title><source>JAMA</source><year>2002</year><volume>293</volume><fpage>2932</fpage><lpage>2934</lpage></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacey</surname><given-names>LA</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>O'shea</surname><given-names>D</given-names></name><name><surname>Erny</surname><given-names>S</given-names></name><name><surname>Ruof</surname><given-names>J</given-names></name></person-group><article-title>Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland</article-title><source>Int J Obes</source><year>2005</year><volume>29</volume><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0802947</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swinburn</surname><given-names>BA</given-names></name><name><surname>Carey</surname><given-names>D</given-names></name><name><surname>Hills</surname><given-names>AP</given-names></name><name><surname>Hooper</surname><given-names>M</given-names></name><name><surname>Marks</surname><given-names>S</given-names></name><name><surname>Proietto</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>BJ</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Welborn</surname><given-names>TA</given-names></name><name><surname>Caterson</surname><given-names>ID</given-names></name></person-group><article-title>Effect of orlistat on cardiovascular disease risk in obese adults</article-title><source>Diabetes Obes Metab</source><year>2005</year><volume>7</volume><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">15811142</pub-id><pub-id pub-id-type="doi">10.1111/j.1463-1326.2004.00467.x</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melia</surname><given-names>AT</given-names></name><name><surname>Koss-Twardy</surname><given-names>SG</given-names></name><name><surname>Zhi</surname><given-names>J</given-names></name></person-group><article-title>The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers</article-title><source>J Clin Pharmacol</source><year>1996</year><volume>36</volume><fpage>647</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">8844448</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>1997</year><volume>46</volume><fpage>1061</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">9385873</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>SS</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Gupta</surname><given-names>LP</given-names></name><name><surname>Datta</surname><given-names>IC</given-names></name></person-group><article-title>Studies on Cissus quadrangularis in experimental fracture repair: effect on chemical parameters in blood</article-title><source>Indian J Med Res</source><year>1975</year><volume>63</volume><fpage>824</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">1213779</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deka</surname><given-names>DK</given-names></name><name><surname>Lahon</surname><given-names>LC</given-names></name><name><surname>Saikia</surname><given-names>J</given-names></name><name><surname>Mukit</surname><given-names>A</given-names></name></person-group><article-title>Effect of <italic>Cissus quadrangularis </italic>in accelerating healing process of experimentally fractured radius-ulna of dog, a preliminary study</article-title><source>Indian J of Pharmacol</source><year>1994</year><volume>26</volume><fpage>44</fpage><lpage>45</lpage></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Udupa</surname><given-names>KN</given-names></name><name><surname>Prasad</surname><given-names>GC</given-names></name></person-group><article-title>Further studies on the effect of Cissus quadrangularis in accelerating fracture healing</article-title><source>Indian J Med Res</source><year>1964</year><volume>52</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">14112159</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Udupa</surname><given-names>KN</given-names></name><name><surname>Prasad</surname><given-names>GC</given-names></name></person-group><article-title>Biomechanical and calcium 45 studies on the effect of Cissus quadrangularis in fracture repair</article-title><source>Indian J Med Res</source><year>1964</year><volume>52</volume><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">14175605</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Udupa</surname><given-names>KN</given-names></name><name><surname>Prasad</surname><given-names>GC</given-names></name></person-group><article-title>Effect of Cissus quadrangularis on the healing of cortisone treated fractures</article-title><source>Indian J Med Res</source><year>1963</year><volume>51</volume><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">14073618</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Udupa</surname><given-names>KN</given-names></name><name><surname>Prasad</surname><given-names>GC</given-names></name></person-group><article-title>Cissus quadrangularis in healing of fractures. A clinical study</article-title><source>J Indian Med Assoc</source><year>1962</year><volume>38</volume><fpage>590</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">13923449</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chidambara Murthy</surname><given-names>KN</given-names></name><name><surname>Vanitha</surname><given-names>A</given-names></name><name><surname>Mahadeva Swamy</surname><given-names>M</given-names></name><name><surname>Ravishankar</surname><given-names>GA</given-names></name></person-group><article-title>Antioxidant and antimicrobial activity of cissus quadrangularis L</article-title><source>J Med Food</source><year>2003</year><volume>6</volume><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">12935320</pub-id><pub-id pub-id-type="doi">10.1089/109662003322233495</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>PK</given-names></name><name><surname>Sanyal</surname><given-names>AK</given-names></name></person-group><article-title>Studies on Cissus quadrangularis linn, acetylcholine like action of the total extract</article-title><source>Indian J Med Res</source><year>1964</year><volume>52</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">14112165</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Dixit</surname><given-names>KS</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Kohli</surname><given-names>RP</given-names></name></person-group><article-title>An experimentally study of analgesic activity of Cissus quadrangularis</article-title><source>Indian J of Pharmacol</source><year>1984</year><volume>79</volume><fpage>162</fpage><lpage>163</lpage></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver-Bever</surname><given-names>B</given-names></name></person-group><article-title>Medicinal plants in tropical West Africa. II. Plants acting on the nervous system</article-title><source>J Ethnopharmacol</source><year>1983</year><volume>7</volume><fpage>1</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">6132025</pub-id><pub-id pub-id-type="doi">10.1016/0378-8741(83)90082-X</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver-Bever</surname><given-names>B</given-names></name></person-group><article-title>Medicinal plants in tropical West Africa. III. Anti-infection therapy with higher plants</article-title><source>J Ethnopharmacol</source><year>1983</year><volume>9</volume><fpage>1</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">6668951</pub-id><pub-id pub-id-type="doi">10.1016/0378-8741(83)90028-4</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramaamurthy</surname><given-names>B</given-names></name><name><surname>Seshadri</surname><given-names>T</given-names></name></person-group><article-title>Carotene content of <italic>Vitis quadrangularis</italic></article-title><source>Proceedings of the Indian Academy of Sciences</source><year>1939</year><volume>9</volume><fpage>121</fpage><lpage>127</lpage></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>SP</given-names></name></person-group><article-title>Study of the active constituents (ketosteroids) of <italic>Cissus quadrangularis</italic></article-title><source>Indian J of Pharmacol</source><year>1964</year><volume>4</volume><fpage>247</fpage></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>M</given-names></name><name><surname>Kaur</surname><given-names>N</given-names></name><name><surname>Bhutani</surname><given-names>KK</given-names></name></person-group><article-title>Determination of marker constituents from <italic>Cissus quadrangularis </italic>Linn. and their quantitation by HPTLC and HPLC</article-title><source>Phytochem Anal</source><year>2001</year><volume>12</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">11705245</pub-id><pub-id pub-id-type="doi">10.1002/pca.569</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shirwaikar</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Malini</surname><given-names>S</given-names></name></person-group><article-title>Antiosteoporotic effect of ethanol extract of Cissus quadrangularis Linn. on ovariectomized rat</article-title><source>J Ethnopharmacol</source><year>2003</year><volume>89</volume><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">14611887</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2003.08.004</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Dardevet</surname><given-names>D</given-names></name><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Ralliere</surname><given-names>c</given-names></name><name><surname>Claustre</surname><given-names>A</given-names></name><name><surname>Grizard</surname><given-names>J</given-names></name><name><surname>attaix</surname><given-names>D</given-names></name></person-group><article-title>Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles</article-title><source>Biochem J</source><year>2004</year><volume>378</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">14636157</pub-id><pub-id pub-id-type="doi">10.1042/BJ20031660</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dulloo</surname><given-names>AG</given-names></name><name><surname>Duret</surname><given-names>C</given-names></name><name><surname>Rohrer</surname><given-names>D</given-names></name><name><surname>Girardier</surname><given-names>L</given-names></name><name><surname>mensi</surname><given-names>N</given-names></name></person-group><article-title>Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans</article-title><source>Am J Clin Nutr</source><year>1999</year><volume>70</volume><fpage>1040</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">10584049</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dulloo</surname><given-names>AG</given-names></name><name><surname>Seydoux</surname><given-names>J</given-names></name><name><surname>Girardier</surname><given-names>L</given-names></name><name><surname>Chantre</surname><given-names>P</given-names></name><name><surname>vandermander</surname><given-names>J</given-names></name></person-group><article-title>Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity</article-title><source>Int J Obes Relat Metab Disord</source><year>2000</year><volume>24</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">10702779</pub-id><pub-id pub-id-type="doi">10.1038/sj.ijo.0801101</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JW</given-names></name><name><surname>Johnstone</surname><given-names>BM</given-names></name><name><surname>Cook-Newell</surname><given-names>ME</given-names></name></person-group><article-title>Meta-analysis of the effects of soy protein intake on serum lipids</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">7596371</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199508033330502</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RA</given-names></name></person-group><article-title>Chromium as an essential nutrient for humans</article-title><source>Regul Toxicol Pharmacol</source><year>1997</year><volume>26</volume><fpage>S35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1006/rtph.1997.1136</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Sreejayan</surname><given-names>N</given-names></name></person-group><article-title>Insulin-sensitizing and cholesterol-lowering effects of chromium (d-Phenylalanine)(3)</article-title><source>J Inorg Biochem</source><year>2006</year><volume>100</volume><fpage>1187</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">16545457</pub-id><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2006.01.039</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name></person-group><article-title>The importance of selenium to human health</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>233</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10963212</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02490-9</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manore</surname><given-names>MM</given-names></name></person-group><article-title>Effect of physical activity on thiamine, riboflavin, and vitamin B-6 requirements</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>72</volume><fpage>598S</fpage><lpage>606S</lpage><pub-id pub-id-type="pmid">10919966</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seshadri</surname><given-names>N</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name></person-group><article-title>Homocysteine, B vitamins, and coronary artery disease</article-title><source>Med Clin North Am</source><year>2000</year><volume>84</volume><fpage>215</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">10685136</pub-id><pub-id pub-id-type="doi">10.1016/S0025-7125(05)70215-7</pub-id></citation></ref><ref id="B47"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Oben</surname><given-names>J</given-names></name><name><surname>Mandob</surname><given-names>D</given-names></name><name><surname>Fomekong</surname><given-names>G</given-names></name><name><surname>Agbor</surname><given-names>G</given-names></name><name><surname>Momo</surname><given-names>C</given-names></name></person-group><article-title>The effect of an extract of <italic>Cissus quadrangularis </italic>on weight and serum lipids in obese patients in Cameroon: a randomized double blind clinical trial</article-title><comment>Publication in progress (submitted to Diabetes Obes Metab 2006)</comment></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>V</given-names></name><name><surname>Scheckenbach</surname><given-names>R</given-names></name><name><surname>Preuss</surname><given-names>HG</given-names></name></person-group><article-title>Effects of niacin-bound chromium supplementation on body composition in overweight African-American women</article-title><source>Diabetes Obes Metab</source><year>1999</year><volume>1</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">11225649</pub-id><pub-id pub-id-type="doi">10.1046/j.1463-1326.1999.00055.x</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefavi</surname><given-names>RG</given-names></name><name><surname>Anderson</surname><given-names>RA</given-names></name><name><surname>Keith</surname><given-names>RE</given-names></name><name><surname>Wilson</surname><given-names>GD</given-names></name><name><surname>McMillan</surname><given-names>JL</given-names></name><name><surname>Stone</surname><given-names>MH</given-names></name></person-group><article-title>Efficacy of chromium supplementation in athletes: emphasis on anabolism</article-title><source>Int J Sport Nutr</source><year>1992</year><volume>2</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">1299487</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>KE</given-names></name><name><surname>Chandler</surname><given-names>RM</given-names></name><name><surname>Castle</surname><given-names>AL</given-names></name><name><surname>Ivy</surname><given-names>JL</given-names></name></person-group><article-title>Chromium and exercise training: effect on obese women</article-title><source>Med Sci Sports Exerc</source><year>1997</year><volume>29</volume><fpage>992</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">9268955</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group><article-title>Incidence and epidemiology of heart failure</article-title><source>Heart Fail Rev</source><year>2000</year><volume>5</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">16228142</pub-id><pub-id pub-id-type="doi">10.1023/A:1009884820941</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>WS</given-names></name><name><surname>Lim</surname><given-names>IH</given-names></name><name><surname>Yuk</surname><given-names>DY</given-names></name><name><surname>Chung</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>JB</given-names></name><name><surname>Yoo</surname><given-names>HS</given-names></name><name><surname>Yun</surname><given-names>YP</given-names></name></person-group><article-title>Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate</article-title><source>Throm Res</source><year>1999</year><volume>96</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/S0049-3848(99)00104-8</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>I</given-names></name><name><surname>Umegaki</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name></person-group><article-title>Green tea polyphenols (flavan 3-ols) prevent oxidative modification of low density lipoproteins: an ex vivo study in humans</article-title><source>J Nutr Biochem</source><year>2000</year><volume>11</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">10827344</pub-id><pub-id pub-id-type="doi">10.1016/S0955-2863(00)00068-1</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haffner</surname><given-names>SM</given-names></name></person-group><article-title>The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease</article-title><source>Am J Cardiol</source><year>2006</year><volume>97</volume><fpage>3A</fpage><lpage>11A</lpage><pub-id pub-id-type="pmid">16675316</pub-id><pub-id pub-id-type="doi">10.1016/j.amjcard.2005.11.010</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>DT</given-names></name></person-group><article-title>Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins</article-title><source>J Natl Med Assoc</source><year>2005</year><volume>97</volume><fpage>1600</fpage><lpage>1607</lpage><pub-id pub-id-type="pmid">16396052</pub-id></citation></ref></ref-list></back></article>


